Access and reimbursement pathways for digital health solutions and IVD devices

Access and reimbursement pathways for digital health solutions and in vitro diagnostic devices: Current scenario and challenges

Digital therapeutics (DTx) are innovative solutions that use meaningful data to provide evidence-based decisions for the prevention, treatment, and management of diseases. Particular attention is paid to software-based in vitro diagnostics (IVDs). With this point of view, a strong connection between DTx and IVDs is observed.

The recent paper “Access and reimbursement pathways for digital health solutions and in vitro diagnostic devices: Current scenario and challenges” investigates the current regulatory scenarios and reimbursement approaches adopted for DTx and IVDs.

The initial assumption was that countries apply different regulations for the access to the market and adopt different reimbursement systems for both DTx and IVDs. The final aim was to provide a general comparative overview and identify those aspects that should be better addressed to support the adoption and commercialization of DTx and IVDs.

The paper “Access and reimbursement pathways for digital health solutions and in vitro diagnostic devices: Current scenario and challenges” is co-authored by Andrea Mantovani, Claudia Leopaldi, and Cassandra Maria Nighswander from Alira Health and Rossella Di Bidino, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Graduate School of Health Economics and Management (ALTEMS).

Related news

Events February 21, 2024
XXII Conferenza Nazionale Sulla Farmaceutica
Meet Giovanni Firenze, Partner Consulting Italy, onsite in Catania and learn more about the impact of the new AIFA reform.
Italy Regulatory
Events February 20, 2024
World EPA Congress Europe
Look for market access and pricing experts Ahmad Bechara and Andrea Mantovani representing Alira Health on the agenda at World EPA Congress.
Market Access Pricing Real-World Evidence (RWE)
News January 24, 2024
Alira Health and AseBio Announce Market Access Mentoring Program for 2024
Alira Health and AseBio, the Spanish Bioindustry Association, are pleased to announce the 2024 edition of their market access mentoring program for AseBio members.
Biotech Market Access Spain Startups
Case Studies January 18, 2024
Pharma Company Succeeds in Adding Medicine to World Health Organization Essential Medicines List
A pharma company with a blood disorder treatment needed support to submit a value dossier to the WHO to add a medicine to the Essential Medicines List.
Market Access Pharma
News January 18, 2024
Alira Health and Biocat Announce Startup Support Program for 2024
Alira Health and Biocat, a strategic stakeholder building the Catalan life sciences and ecosystem, partnered to foster Market Access for startups.
Market Access Startups
Events January 17, 2024
Presentation: Pilot Project for the Inclusion of the Patient Voices in the Regional Market Access Drug Committees in Spain
On January 23rd we will present the results of the first phase of the “Pilot Project for the Inclusion of the Patient Voices in the Regional Market Access Drug Committees in Spain.”
Market Access Patient Engagement Spain
News January 11, 2024
Alira Health and Sancare Join Forces to Drive Healthcare Innovation in France
Alira Health, a global advisory and clinical research firm, and Sancare, an award-winning firm whose mission is to harness the potential of hospital data through artificial intelligence(...)
Healthcare Technology Hospitals Research and Development
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.